Drugs / PF-07868489
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06137742 | Nov 2023 → Sep 2026 overdue | pulmonary arterial hypertension | Pfizer | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07073820 | Nov 2025 → Jul 2028 expected | pulmonary hypertension | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07868489 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06137742 ↗ |
| Route | Subcutaneous | “single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)” NCT06137742 ↗ |